Pluri (PLUR) Shares Outstanding (Weighted Average) (2010 - 2025)
Pluri (PLUR) reported Shares Outstanding (Weighted Average) of $9.3 million for Q4 2025, up 68.19% year-over-year from $5.5 million in Q4 2024, and up 2.94% quarter-over-quarter from $9.0 million in Q3 2025.
Pluri (PLUR) Shares Outstanding (Weighted Average) (2010 - 2025) Analysis & Trends
Pluri (PLUR) has 16 years of Shares Outstanding (Weighted Average) data on file, last reported at $9.3 million in Q4 2025.
- Shares Outstanding (Weighted Average) for Q4 2025 came in at $9.3 million, up 68.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.3 million (up 68.19% YoY), and the FY2025 annual result was $6.3 million, up 20.93% from the prior year.
- Shares Outstanding (Weighted Average) advanced to $9.3 million in Q4 2025 per PLUR's latest filing, from $9.0 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $32.9 million in Q4 2022 and troughed at $4.6 million in Q2 2023.
- A 5-year average of $16.0 million and a median of $7.7 million in 2025 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) sank 85.77% in 2023, then jumped 68.19% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $32.1 million in 2021, then increased by 2.53% to $32.9 million in 2022, then plunged by 84.21% to $5.2 million in 2023, then rose by 6.07% to $5.5 million in 2024, then surged by 68.19% to $9.3 million in 2025.
- Business Quant data shows PLUR's Shares Outstanding (Weighted Average) at $9.3 million in Q4 2025, $9.0 million in Q3 2025, and $6.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 928.40 Mn |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 | 9.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.26 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 6.34 Mn |
| Mar 31, 2025 | 5.86 Mn |
| Dec 31, 2024 | 5.51 Mn |
| Sep 30, 2024 | 5.46 Mn |
| Jun 30, 2024 | 5.24 Mn |
| Mar 31, 2024 | 5.19 Mn |
| Dec 31, 2023 | 5.19 Mn |
| Sep 30, 2023 | 5.17 Mn |
| Jun 30, 2023 | 4.58 Mn |
| Mar 31, 2023 | 4.99 Mn |
| Dec 31, 2022 | 32.88 Mn |
| Sep 30, 2022 | 32.56 Mn |
| Jun 30, 2022 | 32.19 Mn |
| Mar 31, 2022 | 32.13 Mn |
| Dec 31, 2021 | 32.07 Mn |
| Sep 30, 2021 | 32.00 Mn |
| Jun 30, 2021 | 28.11 Mn |
| Mar 31, 2021 | 26.94 Mn |